Wilmington DE Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Wilmington DE
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Wilmington DE News
Children’s Museum of Wilmington hosting Science at Play event
The Children’s Museum of Wilmington will host its annual “Science at Play” event as part of the North Carolina Science Festival.
Pressure Ulcers Market to Reach .6 Billion by 2031, Growing at 4.2% CAGR - Allied Market Research
According to a recent report published by Allied Market Research, titled 'Pressure Ulcers Market,' the global pressure ulcers market was ...
Why we must invest to sustain Delaware life science firms | Opinion
Delaware is the best place for life science innovation and investment to thrive. Our homegrown life science firms need sustained investment.
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company ...